HLA-C and neoplasm: Specifically, once patient NGS data are obtained, it is feasible to enter an ACT-targeted tumor antigen prediction pipeline comprising abnormal peptide prediction, HLA typing, antigen-MHC binding affinity, and neoantigen prioritization.